propranolol has been researched along with Melanoma in 18 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 9.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 7.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "Propranolol is a vasoactive drug that shows antiangiogenic and antitumour activities in melanoma." | 7.85 | Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice. ( Bearzi, C; Buoncervello, M; Catalano, L; Gabriele, L; Giordani, L; Maccari, S; Macchia, D; Marano, G; Rampin, A; Rizzi, R; Spada, M; Stati, T, 2017) |
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 5.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| " Using pharmacological approaches, evaluation of Ki-67 expression by flow cytometry and luciferase-based cAMP assay, we found that treatment with isoproterenol, a β-AR agonist, increased cAMP levels in B16F10 melanoma cells without affecting cell proliferation." | 4.12 | Crosstalk between β2- and α2-Adrenergic Receptors in the Regulation of B16F10 Melanoma Cell Proliferation. ( Ambrosio, C; Ascione, B; Grò, MC; Maccari, S; Marano, G; Matarrese, P; Molinari, P; Stati, T; Vezzi, V; Vona, R, 2022) |
| " Here, we investigated the effects of SNS signaling in murine monocyte-derived macrophages (moMФ) and dendritic cells (DCs) and further combined the nonspecific β-blocker propranolol with a peptide cancer vaccine for the treatment of melanoma in mice." | 4.02 | The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells. ( Chen, SH; Chen, Z; Hinkle, L; Liu, Y; Mai, J; Meng, C; Pan, PY; Shen, H; Xu, Y; Zhang, L, 2021) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 3.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "Propranolol is a vasoactive drug that shows antiangiogenic and antitumour activities in melanoma." | 3.85 | Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice. ( Bearzi, C; Buoncervello, M; Catalano, L; Gabriele, L; Giordani, L; Maccari, S; Macchia, D; Marano, G; Rampin, A; Rizzi, R; Spada, M; Stati, T, 2017) |
| "A 45-year-old woman with marital and working troubles, a personal history positive for malignant melanoma, and a family history of vitiligo presented with adrenergic urticaria (AU), which at first responded to propranolol, but later became unresponsive to both ?-blockers and antihistamines." | 3.78 | Adrenergic urticaria and rheumatoid arthritis in a patient with melanoma: an intricate medical management. ( Capella, GL, 2012) |
| "Different pharmacologic drugs (isadrin, obsidan, phentolamine) changing adrenergic processes are shown to have different effect on the growth and development of lung metastases." | 3.67 | [Changes in the metastasis of experimental tumors and in the antimetastatic effect of cytostatics in their pharmacological action on adrenergic processes]. ( Balitskiĭ, KP; Riabukha, VN; Smelkova, MI; Veksler, IG, 1984) |
| "Congenital or atypical nevi of the child benefit from genetic progress or improvement of clinical knowledge." | 2.49 | [What’s new in pediatric dermatology?]. ( Lacour, JP, 2013) |
| "Propranolol was tested on four UM and two CM cell lines to determine the effects of this beta-blocker." | 1.51 | Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma. ( Burnier, JV; Burnier, MN; Bustamante, P; de Alba Graue, PG; Dias, AB; Goyeneche, A; Jin, E; Miyamoto, D; Tsering, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Q | 1 |
| Long, J | 1 |
| Hu, L | 1 |
| Chen, Z | 2 |
| Li, Q | 1 |
| Hu, G | 1 |
| Maccari, S | 3 |
| Buoncervello, M | 2 |
| Ascione, B | 2 |
| Stati, T | 3 |
| Macchia, D | 2 |
| Fidanza, S | 1 |
| Catalano, L | 2 |
| Matarrese, P | 2 |
| Gabriele, L | 2 |
| Marano, G | 3 |
| Hinkle, L | 1 |
| Liu, Y | 1 |
| Meng, C | 1 |
| Mai, J | 1 |
| Zhang, L | 2 |
| Xu, Y | 1 |
| Pan, PY | 1 |
| Chen, SH | 1 |
| Shen, H | 1 |
| Vona, R | 1 |
| Vezzi, V | 1 |
| Grò, MC | 1 |
| Ambrosio, C | 1 |
| Molinari, P | 1 |
| Bustamante, P | 1 |
| Miyamoto, D | 1 |
| Goyeneche, A | 1 |
| de Alba Graue, PG | 1 |
| Jin, E | 1 |
| Tsering, T | 1 |
| Dias, AB | 1 |
| Burnier, MN | 1 |
| Burnier, JV | 1 |
| Gandhi, S | 1 |
| Pandey, MR | 1 |
| Attwood, K | 1 |
| Ji, W | 1 |
| Witkiewicz, AK | 1 |
| Knudsen, ES | 1 |
| Allen, C | 1 |
| Tario, JD | 1 |
| Wallace, PK | 1 |
| Cedeno, CD | 1 |
| Levis, M | 1 |
| Stack, S | 1 |
| Funchain, P | 1 |
| Drabick, JJ | 1 |
| Bucsek, MJ | 1 |
| Puzanov, I | 1 |
| Mohammadpour, H | 1 |
| Repasky, EA | 1 |
| Ernstoff, MS | 1 |
| De Giorgi, V | 3 |
| Grazzini, M | 2 |
| Benemei, S | 3 |
| Marchionni, N | 2 |
| Botteri, E | 1 |
| Pennacchioli, E | 1 |
| Geppetti, P | 3 |
| Gandini, S | 2 |
| Patanè, S | 1 |
| Kao, J | 1 |
| Luu, B | 1 |
| Lacour, JP | 1 |
| Wrobel, LJ | 1 |
| Le Gal, FA | 1 |
| Zhou, C | 1 |
| Chen, X | 1 |
| Zeng, W | 1 |
| Peng, C | 1 |
| Huang, G | 1 |
| Li, X | 1 |
| Ouyang, Z | 1 |
| Luo, Y | 1 |
| Xu, X | 1 |
| Xu, B | 1 |
| Wang, W | 1 |
| He, R | 1 |
| Zhang, X | 1 |
| Liu, J | 1 |
| Knepper, TC | 1 |
| He, Y | 1 |
| McLeod, HL | 1 |
| Rampin, A | 1 |
| Spada, M | 1 |
| Giordani, L | 1 |
| Bearzi, C | 1 |
| Rizzi, R | 1 |
| Fraser, K | 1 |
| Capella, GL | 1 |
| Veksler, IG | 1 |
| Riabukha, VN | 1 |
| Smelkova, MI | 1 |
| Balitskiĭ, KP | 1 |
2 reviews available for propranolol and Melanoma
| Article | Year |
|---|---|
Can propranolol prevent progression of melanoma?
Topics: Adrenergic beta-Antagonists; Disease Progression; Humans; Melanoma; Neoplasm Recurrence, Local; Prop | 2019 |
[What’s new in pediatric dermatology?].
Topics: Adolescent; Child; Dermatitis, Atopic; Dermatology; Hemangioma, Capillary; Humans; Melanoma; Neoplas | 2013 |
1 trial available for propranolol and Melanoma
| Article | Year |
|---|---|
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
15 other studies available for propranolol and Melanoma
| Article | Year |
|---|---|
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dru | 2020 |
α-Adrenoceptor stimulation attenuates melanoma growth in mice.
Topics: Animals; Catecholamines; Epinephrine; Ligands; Melanoma; Mice; Mice, Knockout; Propranolol; Receptor | 2022 |
The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells.
Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Dendritic Cells; Melanoma; Mice; Monocytes; No | 2021 |
Crosstalk between β2- and α2-Adrenergic Receptors in the Regulation of B16F10 Melanoma Cell Proliferation.
Topics: Adrenergic beta-Agonists; Cell Line, Tumor; Cell Proliferation; Humans; Isoproterenol; Melanoma; Pro | 2022 |
Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.
Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Sc | 2019 |
Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.
Topics: Aged; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Mi | 2018 |
Improving the Propranolol Treatment of Melanoma-Reply.
Topics: Cell Proliferation; Cohort Studies; Humans; Melanoma; Off-Label Use; Propranolol | 2018 |
Improving the Propranolol Treatment of Melanoma.
Topics: Cell Proliferation; Cohort Studies; Humans; Melanoma; Off-Label Use; Propranolol | 2018 |
Inhibition of human melanoma growth by a non-cardioselective β-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; | 2015 |
Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; G1 | 2016 |
Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Resp | 2017 |
67th annual meeting of the American Academy of Dermatology: San Francisco, California, USA, 6-10 March 2009.
Topics: Acne Vulgaris; Dermatology; Hemangioma; Humans; Keratosis, Actinic; Melanoma; Methicillin-Resistant | 2009 |
[β-blockers: a new and emerging treatment for melanoma].
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Evidenc | 2012 |
Adrenergic urticaria and rheumatoid arthritis in a patient with melanoma: an intricate medical management.
Topics: Adrenergic beta-Antagonists; Arthritis, Rheumatoid; Female; Glucocorticoids; Histamine Antagonists; | 2012 |
[Changes in the metastasis of experimental tumors and in the antimetastatic effect of cytostatics in their pharmacological action on adrenergic processes].
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Evaluation, Preclinical; Drug Therapy, Combin | 1984 |